Hikma Pharmaceuticals Plc Director/PDMR Shareholding
24 Septembre 2024 - 11:09AM
RNS Regulatory News
RNS Number : 4246F
Hikma Pharmaceuticals Plc
24 September 2024
Hikma Pharmaceuticals
PLC
(the
"Company")
LONDON, 24 September 2024:
Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai:
HIK) (LEI: 549300BNS685UXH4JI75) announces
that the below listed Persons Discharging Managerial Responsibility
("PDMRs") of the Company
acquired Ordinary Shares in the Company,
which were purchased under a dividend reinvestment plan
("DRIP").
This notification is made under
Article 19(1) of the EU Market Abuse Regulation 596/2014 as it
forms part of domestic law by virtue of the European Union
(Withdrawal) Act 2018 ("MAR"). The
information set out below is provided in accordance with the
requirements of Article 19(3) of MAR.
Notification and public
disclosure of transactions by persons discharging managerial
responsibilities
Riad
Mishlawi
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Riad Mishlawi
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Hikma Pharmaceuticals PLC
|
|
b)
|
LEI
|
549300BNS685UXH4JI75
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument and identification code
|
Description: Ordinary shares of 10
pence each (Shares)
ID Code: GB00B0LCW083
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares
through participation in a DRIP.
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
£19.03
|
509
|
|
d)
|
Aggregated information
|
Price(s): £19.03
Volume(s): 509
Total: £9,685.55
|
|
e)
|
Date of the transaction
|
23 September 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange
(XLON)
|
Hussein
Arkhagha
|
1
|
Details of the person discharging managerial
responsibilities / person closely
associated
|
|
a)
|
Name
|
Hussein Arkhagha
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
PDMR
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Hikma Pharmaceuticals
PLC
|
|
b)
|
LEI
|
549300BNS685UXH4JI75
|
|
4
|
Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
|
a)
|
Description of the financial
instrument, type of instrument and identification code
|
Description: Ordinary shares of
10 pence each (Shares)
ID Code:
GB00B0LCW083
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares
through participation in a DRIP.
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
£19.03
|
206
|
|
d)
|
Aggregated information
|
Price(s): £19.03
Volume(s): 206
Total: £3,919.89
|
|
e)
|
Date of the transaction
|
23 September 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange
(XLON)
|
Susan
Ringdal
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Susan Ringdal
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
PDMR
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Hikma Pharmaceuticals PLC
|
|
b)
|
LEI
|
549300BNS685UXH4JI75
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument and identification code
|
Description: Ordinary shares of 10
pence each (Shares)
ID Code: GB00B0LCW083
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares
through participation in a DRIP.
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
£19.03
|
621
|
|
d)
|
Aggregated information
|
Price(s): £19.03
Volume(s): 621
Total: £11,816.75
|
|
e)
|
Date of the transaction
|
23 September 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange
(XLON)
|
Julie Hill
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Julie Hill
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
PDMR
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Hikma Pharmaceuticals PLC
|
|
b)
|
LEI
|
549300BNS685UXH4JI75
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument and identification code
|
Description: Ordinary shares of 10
pence each (Shares)
ID Code: GB00B0LCW083
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares
through participation in a DRIP.
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
£19.03
|
41
|
|
d)
|
Aggregated information
|
Price(s): £19.03
Volume(s): 41
Total: £780.17
|
|
e)
|
Date of the transaction
|
23 September 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange
(XLON)
|
Helen Middlemist
Group Company Secretary
+44 (0) 20 7399 2760
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHGCGDCIGDDGSS
Hikma Pharmaceuticals (LSE:HIK)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Hikma Pharmaceuticals (LSE:HIK)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
